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The functional roles of SNPs within the 8q24 gene desert in the cancer phenotype are not yet well understood. Here, we
report that CCAT2, a novel long noncoding RNA transcript (lncRNA) encompassing the rs6983267 SNP, is highly over-
expressed in microsatellite-stable colorectal cancer and promotes tumor growth, metastasis, and chromosomal instability.
We demonstrate thatMYC, miR–17–5p, andmiR–20a are up-regulated by CCAT2 through TCF7L2-mediated transcriptional
regulation. We further identify the physical interaction between CCAT2 and TCF7L2 resulting in an enhancement of WNT
signaling activity. We show that CCAT2 is itself a WNT downstream target, which suggests the existence of a feedback loop.
Finally, we demonstrate that the SNP status affects CCAT2 expression and the risk allele G produces more CCAT2 transcript.
Our results support a new mechanism of MYC and WNT regulation by the novel lncRNA CCAT2 in colorectal cancer
pathogenesis, and provide an alternative explanation of the SNP-conferred cancer risk.
[Supplemental material is available for this article.]
Notwithstanding the considerable advancements in our under-
standing of themolecular genetic basis of cancer, in themajority of
cancer-associated genomic regions, the responsible protein-coding
genes have not been identified yet. The discovery of short (19–
22 nt), noncoding RNAs (ncRNAs)—called microRNAs (miRNAs)
(Ambros 2001)—not only revealed a novel mechanism of gene
regulation but also led to the identification of miRNAs directly
involved in cancer development (Spizzo et al. 2009). It is therefore
plausible that as-yet-unidentifiedmembers of the broader category
of ncRNAmapping to cancer-associated genomic regions play rate-
limiting roles in tumor initiation and/or progression (Rinn and
Chang 2012). For instance, we previously reported that highly
conserved genomic regions (ultraconserved regions, or UCRs)
(Bejerano et al. 2004) are frequently transcribed as long (>200 bp)
ncRNAs (lncRNAs) in both normal and tumor tissues (Calin et al.
2007). Furthermore, germline mutations, as well as single nucle-
otide polymorphisms (SNPs) in ultraconserved ncRNAs, were
found to occur more frequently in patients with colon cancer and
chronic leukemia than in the general population (Wojcik et al.
2010).
The rs6983267 SNP, mapping to the 8q24.21 chromosomal
region, has been consistently associated with an increased risk of
colorectal cancer (CRC) (Haiman et al. 2007): The G allele was as-
sociated with greater predisposition to CRC than the T allele (odds
ratios of 1.27 and 1.47 for heterozygotes and homozygotes, re-
spectively; P = 1.273 1014) (Tomlinson et al. 2007). The increased
cancer risk from this SNP variant was also observed in other cancer
types, including prostate, ovarian, and inflammatory breast cancer
(Ghoussaini et al. 2008; Bertucci et al. 2012). Despite the consistent
association between rs6983267 and cancer risk, the underlying
molecular and cellular mechanisms remain largely unknown. The
genomic region spanning rs6983267 was found to contain DNA
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enhancer elements (Pomerantz et al. 2009; Tuupanen et al. 2009),
and the allelic variants were shown to confer different binding
affinity to TCF7L2 (transcription factor 7-like 2 [T-cell specific,
HMG-box]), a transcription factor that, together with CTNNB1,
plays a central role in the transcriptional activation of WNT target
genes. In view of the well-established role of constitutive WNT
signaling activation in CRC, these findings suggest that rs6983267
itself resides in a functional element that directly participates in
colon cancer pathogenesis.
On the base of the localization of rs6983267 within a highly
conserved region of the genome (http://genome.ucsc.edu) (Sotelo
et al. 2010) and our previous report of transcription in UCRs (Calin
et al. 2007), we hypothesized that an as-yet-unidentified, highly
conserved ncRNA could be transcribed from this genomic region.
The association between rs6983267 and CRC risk further sug-
gested that this ncRNA is likely to be aberrantly expressed in
colon cancer and to play a role in CRC carcinogenesis through
WNT signaling.
Results
CCAT2, a novel lncRNA transcript maps to the highly conserved
8q24.21 region encompassing rs6983267 and is overexpressed
in microsatellite-stable CRC samples
The 8q24.21 genomic region encompasses a highly conserved
segment with homologies found in 28 species-conserved tracks
(University of California, Santa Cruz Genome Browser; http://
genome.ucsc.edu/) (Fig. 1A). We designed primers spanning the
Figure 1. CCAT2, a novel lncRNA spanning rs6983267, is overexpressed in colorectal cancer samples. (A) Genomic features of the 8q24.21 region
spanning SNP rs6983267 and the genomic location of CCAT2. Numbers in parentheses show the genomic distance relative to rs6983267 (image not to
scale). (B) CCAT2 expression in CRC patient samples. CCAT2 expression was quantified using qRT-PCR, and data are presented as box-whisker plots
showing the five statistics (lower whisker is 5% minimum, lower box part is the 25th percentile, solid line in box represents the median, upper box part is
75th percentile, and upper whisker is 95% maximum). (C ) In situ hybridization of CCAT2 and RNU6-6P (U6) (as normalizer) in CRC patient samples.
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rs6983267 SNP and found that this region was transcribed at high
levels in human pancreas, lung, prostate, and testis tissues (data
not shown). Subsequently, we cloned by RACE (rapid amplifica-
tion of cDNA ends) a 340-bp nonspliced transcript from bone
marrow cDNA (Fig. 1A). To exclude the possibility that this tran-
script was part of long intergenic noncoding RNAs (lincRNAs)
mapped in this region (RP11-382A18.2 and RP11-382A18.1), we
performed polymerase chain reaction (PCR) amplification using
lincRNA-specific primers combined with primers from within
the 340-bp transcript.We did not observe any amplified product in
the COLO320 colon cancer cell line that expresses the highest
levels of the newly identified transcript, suggesting that it is dis-
tinct from the two lincRNAs. We further cloned an intronless
630-bp transcript from mouse testis cDNA. Notably, the sequence
overlapping between the transcripts cloned from the human
and mouse tissues shared 93% homology and encompassed the
rs6983267 SNP.
Because a previous study using a tiling assay did not find any
transcriptional activity in this region (Pomerantz et al. 2009), we
sought other independent data to support the existence of this
newly identified RNA transcript. By searching the Long RNA-seq
data from ENCODE/CSHL (http://genome.ucsc.edu/; Djebali et al.
2012), we found that the rs6983267 region is actively transcribed
in the genomic sense orientation in GM12878 lymphoblastoid
cells (Supplemental Fig. S1). We next determined whether this
transcript has protein-coding potential. The transcript’s non-
coding nature was suggested by the negative results of the in vitro
translation assay, along with the lack of consistent open reading
frames (ORFs) by ORF Finder (http://www.ncbi.nlm.nih.gov/gorf/
gorf.html), negative score by PhyloCSF (271.5366, meaning that
CCAT2 is 1027.15366 times more likely to be a noncoding sequence
than a coding one), a comparative genomicmethod differentiating
coding and noncoding RNA (Lin et al. 2011), lack of coding po-
tential determined by coding potential assessment tool (CPAT;
http://lilab.research.bcm.edu/cpat/) (Wang et al. 2013), and neg-
ative data from the small-peptide database (Pepbank; http://
pepbank.mgh.harvard.edu/search/blast) (Supplemental Fig. S2A).
We further confirmed the existence of this novel RNA by using
Northern blot analysis on a panel of colon cancer cell lines probed
by sense-specific oligonucleotides spanning rs6983267: A tran-
script of ;400 bp in genomic sense orientation (centromere to
telomere) was detected with the highest expression in COLO320
cells (Supplemental Fig. S2B). Consistent with this observation,
Southern blot analysis revealed that among analyzed samples,
COLO320 cells had the highest degree of genomic amplification of
the 8q24 region (data not shown). By taking advantage of a cohort
of nine paired colon specimens, we determined by quantitative
real-time PCR (qRT-PCR) analysis that the newly identified tran-
script was expressed at much higher levels in tumor tissue than in
the adjacent normalmucosa, and confirmed that the transcription
occurs in the genomic sense orientation (Supplemental Fig. S2C).
We named this novel gene transcript colon cancer–associated
transcript 2 (CCAT2).
We further measured CCAT2 expression by qRT-PCR in 215
CRC and 94 paired non-neoplastic mucosal specimens obtained
from patients from four different geographical regions (i.e., Italy,
Japan, Australia, and North America). We identified significantly
higher CCAT2 expression in the CRC tissue as compared with the
adjacent mucosae (Fig. 1B). Moreover, microsatellite-stable (MSS)
cancers had higher CCAT2 expression (approximately 10 times)
than microsatellite-unstable (MSI-H) tumors and adjacent normal
colon mucosae (Fig. 1B; Supplemental Fig. S2C). To visualize
CCAT2 expression, we performed in situ hybridization by using
a locked nucleic acid probe designed against CCAT2 RNA. In
agreement with the qRT-PCR findings (Fig. 1B), the epithelial ex-
pression pattern observed had stronger staining in MSS than in
MSI-H cancers and normal mucosae (Fig. 1C). We did not observe
a significant association between CCAT2 expression and genomic
DNA amplification in an additional set of CRC samples from Japan
(n = 64, P = 0.46) (Supplemental Fig. S2D), suggesting that CCAT2
expression is, at least partially, independent of the genomic DNA
copy number alterations in this chromosomal region.
CCAT2 promotes cancer growth and metastasis
To test the hypothesis thatCCAT2 plays an oncogenic role in CRC,
we cloned CCAT2 into a retroviral expression vector and trans-
duced it into HCT116 colon cancer cells. This is an MSI-H cell line
(MSH6 mutant) with a near-diploid karyotype (Lengauer et al.
1997) that expresses low levels of CCAT2 (when compared with
COLO320) (Supplemental Fig. S2B). Retrovirus transfection of the
CCAT2 construct caused a 630-times increase in CCAT2 expression
compared with the cells transfected with empty vector (Supple-
mental Fig. S3A). For comparison, the expression difference between
high-expresser COLO320 cells and low-expresser HCT116 cells was
about 1500 times (Supplemental Fig. S3A). The CCAT2-transduced
HCT116 cells did not affect cell proliferation in two-dimensional
(2D) culture conditions (Supplemental Fig. S3B), but showed a
growth advantage under low-adherence conditions and increased
colony-forming potential (Supplemental Fig. S3C,D). Subcutaneous
transplantation of CCAT2-overexpressing HCT116 cells resulted in
larger xenograft tumors in Swiss nu-nu/Ncr nude mice when com-
pared with empty vector-transduced cells (Fig. 2A). This observed in
vivo tumor promotion effect of CCAT2 was independently con-
firmed by a xenograft study using pcDNA construct–established
CCAT2-overexpressing HCT116 cells (data not shown).
Wenext studiedwhetherCCAT2 is involved in promoting the
metastatic phenotype in colon cancer cells. The in vitro migration
assay showed a twofold increase in the migration of CCAT2-
transduced HCT116 cells (P = 0.001) (Fig. 2B). To validate the role
of CCAT2 in the metastatic phenotype, we used KM12SM cells,
a CRC cell line established from the spontaneous livermetastasis of
KM12C cells (Camps et al. 2004). Knockdown of CCAT2 by siRNA,
which reduced the CCAT2 expression by 70%, significantly re-
duced the invasive ability of KM12SM cells (that express high
levels of CCAT2), suggesting the involvement of CCAT2 in me-
tastasis (Fig. 2C; Supplemental Fig. S4). More importantly, spleen
injection of CCAT2-overexpressing HCT116 cells into Swiss nu-nu/
Ncr nudemice resulted in a higher incidence of livermetastasis (six
of nine mice vs. one of five mice) as well as a greater number of
metastatic tumors (P = 0.025) than in the control group (Fig. 2D).
These studies suggest that modulation of CCAT2 expression levels
changes the metastatic capacity of cancer cells. In addition, in the
Italian cohort of CRC samples (which was the larger available set),
we found significantly higher CCAT2 expression levels in primary
CRC tumors from patients with metastasis (TNM category M1)
than in those without metastasis (M0; P = 0.003) (Fig. 2E).
To further expand on this issue and in view of the previous
report on the correlation between rs6983267 and breast cancer
aggressiveness (Bertucci et al. 2012), we measured CCAT2 RNA
expression levels in 129 lymph node–positive breast cancer pa-
tients who received an adjuvant cyclophosphamide, methotrexate,
and 5-fluorouracil combination regimen. High CCAT2 RNA levels
were associated with shorter metastasis-free survival when analyzed
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as both a continuous variable (Supplemental Table S1) and as a di-
chotomized variable using themedian level as a cutoff point (Fig. 2F).
CCAT2 induces chromosomal instability
Because chromosomal instability (CIN) represents a main feature
of MSS CRCs, and in view of the high CCAT2 expression levels
among MSS colon cancers (Fig. 1B,C), we hypothesized that
CCAT2 may underlie CIN development. We generated stable
HCT116 clones overexpressing CCAT2 (OC1 and OC2) or with
basal CCAT2 expression (E1 and E2) by using the pcDNA expres-
sion vector (Fig. 3A). Genomic instability analysis showed that the
percentage of cells with normal metaphases was markedly lower
Figure 2. CCAT2 promotes tumor growth and metastasis. (A) CCAT2 increased subcutaneous tumor formation in a mouse xenograft model. Com-
parison was made between the empty vector and CCAT2 groups at the indicated weekly time points using the t-test. (B) HCT116 cells transduced with
CCAT2 showed significantly higher migration ability, as measured by using a migration chamber. Data are presented as mean 6 SEM from three in-
dependent experiments. (C ) Knockdown of CCAT2 reduces invasion ability of KM12SM colon cancer cells. After treatment with CCAT2 siRNA (50 nM) for
24 h, cells were seeded onto an invasion assay chamber for 48 h, and invaded cells were stained and counted. (D) CCAT2 enhances liver metastasis in mice
that were incubated by intrasplenic injection with HCT116 cells. A representative image of liver metastasis from the CCAT2 group is shown. (E ) CCAT2
expression levels in Italian primary CRC samples from patients with metastasis (M1) were higher than those from without metastasis (M0). Comparison
was made using the Mann-Whitney test. Data are presented as box-whisker plots. (F ) Breast cancer patients with high CCAT2 had shorter metastasis-free
survival. Kaplan-Meier analysis as a function of CCAT2 levels in 129 lymph node–positive breast cancer patients who received adjuvant combination
chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil. CCAT2 high level to normalizer, >0.0045; CCAT2 low level, #0.0045.
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in OC (59.5% in OC1 and 31.4% in OC2) than in E (84.2% in E1
and 94.3% in E2) clones (Fig. 3A). In the same analysis, CCAT2
dramatically increased the percentage of polyploid cells from 5.3%
(E1) and 2.8% (E2) to 33.3% (OC1) and 60.0% (OC2) (Fig. 3A). We
detected near-tetraploid status in clone OC2 by spectral karyotype
analysis (Fig. 3B) and observed a doubling of nuclear size and DNA
Figure 3. CCAT2 induces chromosomal instability in HCT116 cells. (A) Increased chromosomal abnormalities in CCAT2-overexpressing clones, as
identified by genomic instability analysis. (B) Example of spectral karyotypes of HCT116 clones revealed a change from the original diploid (E1) to the
tetraploid karyotype in the OC2 clone. (C,D) CCAT2 induces chromosomal instability in an independent set of CCAT2-overexpressing clones. The number
of chromosomal abnormalities in each clone was counted; data are expressed as mean6 SD. (E ) Abnormal centrosomes in CCAT2-overexpressing clones
OC1 and OC2 by immunostaining. Beta-tubulin (red); CREST/kinetochore (green).
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content by DAPI staining and flow cytometric analysis (Supple-
mental Fig. S5A,B). TheCIN-inducing ability byCCAT2was further
validated by a second batch of eight overexpressing clones that
exhibited numerical and structural chromosomal changes (Fig.
3C,D; Supplemental Fig. S5C). CIN was also observed in HCT116
cells transduced with CCAT2-containing retrovirus (Supplemental
Fig. S5D). Stable knockdown of CCAT2 expression in COLO320
cells partially reversed the abnormal metaphase observed in
COLO320 cells (Supplemental Fig. S5E). To further identify
the mechanism by which CCAT2 overexpression may underlie
CIN, we evaluated spindle and CREST/kinetochore structure by
immunocytochemistry analysis of theCCAT2 clones (E1, E2, OC1,
and OC2) with antibodies directed against beta-tubulin and the
centromere. Normal numbers of centrosomes were observed in
both E1 and E2 with spindles separating chromosomes from two
centromeres in the nucleus (Fig. 3E). However, we detected aberrant
numbers of centrosomes pulling chromosomes from three or more
different points in the CCAT2-overexpressing clones (Fig. 3E). The
observed defects in centrosomes are likely to result in abnormal
chromosomal breakage and fusion, and eventually aneuploidy.
Because CIN scores were already available from 218 breast
cancer patients with lymph node–negative disease (Smid et al.
2011), we assessed the CCAT2 expression levels in these tumor
samples. We identified a significant positive correlation between
CCAT2 level and CIN score (Spearman correlation: Rs = 0.17,
P = 0.012).
CCAT2 regulates MYC transcription
To explore the molecular mechanism underlying CCAT2’s onco-
genic potential, we characterized the expression of other tran-
scripts located in the same region: MYC and exons 6 and 8 of
DQ515897 (but not POU5F1B) showed expression patterns similar
to that ofCCAT2, althoughwith smaller differences amongMSI-H,
and MSS cancers and normal colorectal mucosa (Fig. 4A; Supple-
mental Fig. S6A). In view of these associative data and of previous
reports describing a long-range interaction between rs6983267
and MYC (Pomerantz et al. 2009; Sotelo et al. 2010), we asked
whether CCAT2 plays a role in regulatingMYC expression. Among
the HCT116 clones, we found higherMYC expression at both the
RNA andprotein levels in cells overexpressingCCAT2 (3.4-fold and
2.5-fold increases in OC1 and OC2, respectively; P = 0.030 and P =
0.038, respectively) (Fig. 4B). Higher MYC expression was also
found in three additional independent HCT116 clones over-
expressing CCAT2 (Supplemental Fig. S6B). Expression of down-
stream MYC protein-coding gene targets such as BAX (Mitchell
et al. 2000), CDC25A (Galaktionov et al. 1996), and CDKN2A
(Zindy et al. 1998), and the microRNA targets such as MIR17HG
(O’Donnell et al. 2005) andmiR-146a (Chang et al. 2008) were also
changed accordingly (Fig. 4C; Supplemental Fig. S6C,D). Addi-
tionally, the MIR17HG was also up-regulated in retrovirus-trans-
fected cells (Supplemental Fig. S6E) and was significantly reduced
by transient MYC down-regulation (Supplemental Fig. S6F), sug-
gesting that these microRNAs are regulated by MYC in our ex-
perimental systems. Conversely, transient knockdown of CCAT2
reduced MYC expression (both RNA and protein) in CCAT2-
overexpressing clones (Fig. 4D), suggesting that CCAT2 RNA, and
not merely its genomic locus, is required for the maintenance of
highMYC expression levels. In addition, sustained down-regulation
of CCAT2 by shRNA retroviruses decreased MYC expression and
MIR17HG expression in COLO320 cells in a CCAT2-dependent
fashion (Fig. 4E; Supplemental Fig. S6G). This effect was further
validated in Tet-on inducible COLO320 clones, where CCAT2
expression was reduced by specific shRNAs in response to doxy-
cycline (Fig. 4F).
Next, we moved on to determine whether MYC and/or its
targets are mediators of the above-observed CCAT2-driven en-
hanced cell migration. In our experimental system, reducingMYC
expression did not significantly decrease the migration of CCAT2-
transduced cells (Supplemental Fig. S6H). However, consistent
with the consensus that theMIR17HG increasesmetastasis (Bartley
et al. 2011; Zhang et al. 2012), knockdown ofmiR-17-5p ormiR-20a
in CCAT2-overexpressing cells led to a significant decrease in cell
migration (Fig. 4G; Supplemental Fig. S6I). These findings suggest
a not-yet-identified complex network underlying CCAT2-elicited
metastatic phenotype.
Mechanisms of CCAT2 ’s regulatory effect
Because CCAT2’s subcellular localization may provide additional
clues about its functional role, we measured CCAT2 expression in
nuclear and cytosolic fractions from CCAT2-expressing HCT116
subclones and the COLO320 cell line by qRT-PCR. The differ-
ential enrichments of GAPDH and RNU6-6P RNA were used as
fractionation indicators (Supplemental Fig. S7). In these samples,
we found a considerable increase in CCAT2 expression in the
nucleus versus the cytosol, thus indicating that CCAT2 is mainly
localized in the nucleus (Fig. 5A). This was further confirmed by
the in situ hybridization findings in CRC samples (Fig. 5B).
Consistent with our findings, RNA-seq data showed that the
transcript encompassing rs6983267 is exclusively expressed in
the nucleus of GM12878 lymphoblastoid cells (Supplemental
Fig. S1).We also investigated a potential effect of CCAT2 onMYC
mRNA stability (Supplemental Fig. S8), as well as an RNA en-
hancer effect (Supplemental Fig. S9; Supplemental Results;
Orom et al. 2010), but could not find any significant variations
related to CCAT2 levels.
Aberrant WNT activation occurs in the majority of CRCs
(Clevers 2006), and the risk allele of SNP rs6983267 has been
shown to confer enhanced response to WNT signaling through
TCF7L2 binding (Tuupanen et al. 2009). Since MYC is an estab-
lished target of TCF7L2 as confirmed by the presence of TCF7L2-
binding sites in its promoter as well as by functional studies (He
et al. 1998), it is possible that CCAT2 affects MYC expression
through the mediation of TCF7L2. Consistent with previous
findings, we identified TCF7L2 binding to the MYC promoter re-
gion and observed enhanced binding in the OC1 clone when
compared with the E1 clone (Fig. 5C). Next, we sought to de-
termine whether this was due to an increase in nuclear CTNNB1 or
TCF7L2 accumulation. Using Western blot analysis, we observed
a comparable level of total CTNNB1 expression levels with no in-
crease in nuclear CTNNB1 between CCAT2-overexpressing clones
and their control cells (Supplemental Fig. S10). Similarly, TCF7L2
expression levels were comparable in all four clones (Supplemental
Fig. S10). Notably, by using a TOP-Flash luciferase assay, we ob-
served a twofold increase inWNTreporter activity inOC1 andOC2
clones with increased CCAT2 expression levels (Fig. 5D). Increased
luciferase activitywas also observed in an independently generated
set of high-CCAT2-expressing HCT116 clones (Supplemental Fig.
S11). This result was further confirmed in HEK293 WNT reporter
cells transiently transfected with CCAT2 expression vector (Fig.
5E). Consistent with these observations, WNT reporter activity in
COLO320 cells was effectively reduced byCCAT2 siRNAand also as
expected by TCF7L2 siRNA (Supplemental Fig. S12). These find-
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ings suggest thatCCAT2 augments TCF7L2 transcriptional activity
without increasing the quantity of TCF7L2.
We used RNA immunoprecipitation analysis to examine the
physical interaction between CCAT2 and TCF7L2 by pulling
down RNAs colocalized with TCF7L2 protein. We found an en-
richment of CCAT2 RNA, but not GAPDH and the HOTAIR
ncRNA by TCF7L2 antibody compared with the IgG control in
the OC1 clone (Fig. 5F; Supplemental Fig. S13). To test whether
endogenous CCAT2 binds to TCF7L2 protein, we analyzed the
RNA–protein association in COLO320 cells that express high
CCAT2 levels. Similar to the findings in the OC1 HCT116 clone,
a significant enrichment of CCAT2 was observed in TCF7L2 pull-
down RNA samples from COLO320 cells (Fig. 5G; Supplemental
Fig. S13).
Overall, these results suggest that the main mechanism
through which CCAT2 increases MYC expression relies on activa-
tion of WNT signaling by enhancing TCF7L2 transcriptional ac-
tivity. Accordingly, the expression of specific WNT target genes
such as CD44 (Wielenga et al. 1999) and VIM (Gilles et al. 2003)
was increased in CCAT2-overexpressing clones (Fig. 5H,I). Con-
versely, knockdownofCCAT2 expression caused a reduction in the
expression level of VIM in both KM12SM (with high endogenous
CCAT2 expression) and COLO320 (with very high endogenous
CCAT2 expression) cells (Supplemental Fig. S14).
Figure 4. Regulation ofMYC expression by CCAT2. (A) Increased CCAT2 andMYC expression inMSS CRC samples. Expression profile ofMYC and CCAT2
in paired CRC/control mucosa samples from Italy using qRT-PCR. (B) Correlation of MYC protein and CCAT2 RNA levels in HCT116 clones with high and
basal CCAT2 levels. (C ) CCAT2 increased miRNA expression of the MIR17HG, decreased miR-146a expression, and exerted no consistent effect on let-7a
(used as negative control). (D) Down-regulation ofMYC (upper panel: protein; lower panel: RNA) by CCAT2 siRNA in HCT116 OC2 clone. (E ) ReducedMYC
expression in COLO320 shCCAT2 stable clones. (F ) Reduction ofMYC in doxycycline-inducible shCCAT2 clones of COLO320. (G) Reduction ofmigration in
CCAT2-transduced HCT116 cells by anti-miR-17-5p and anti-miR-20a. Twenty-four hours after anti-miR treatment, cells were seeded onto a migration
assay chamber for another 24 h, and migrated cells were stained and counted. (*) P < 0.05.
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CCAT2 responds to WNT signaling
Previously, a TCF7L2-binding element was found to be located
within the rs6983267 genomic span (Pomerantz et al. 2009;
Tuupanen et al. 2009), which suggested that CCAT2 expression
levels might be regulated by this transcription factor. Therefore,
we treated three colon cancer cell lines (COLO320, HCT116, and
RKO) with lithium chloride (LiCl) in order to further activate ca-
nonical WNT signaling through inhibition of glycogen synthesis
kinase 3 beta (GSK3B) (Tuupanen et al. 2009). The effect of LiClwas
monitored by TOP-Flash luciferase activity and by AXIN2 expres-
sion ( Jho et al. 2002). In all these cell lines, we observed an increase
Figure 5. Regulation of TCF7L2 activity by CCAT2. (A) CCAT2 nuclear localization, as identified using qRT-PCR in fractionated COLO320 cells and
HCT116 CCAT2 clones. (B) CCAT2 nuclear localization, as identified in CRC samples using in situ hybridization. (C ) CCAT2 increased TCF7L2 binding to the
MYCpromoter. ChIP analysis showed higher binding inCCAT2-overexpressing clone (OC1) than cells with basalCCAT2 expression (E1). Goat IgGwas used
as a control antibody. (D) HigherWNT activity in CCAT2 stable clones, as identified by TOP-Flash reporter assay. (E ) Transient expression of CCAT2 induced
a more than twofold increase of TOP-Flash luciferase activity in HEK293 cells. The data in C and D are presented as mean 6 SEM (n = 3). (*) P < 0.05. (F )
Colocalization of CCAT2 RNAwith TCF7L2 protein by RNA immunoprecipitation using anti-TCF7L2 antibodies in OC1with ectopic CCAT2 overexpression.
(G) Colocalization of CCAT2 RNA with TCF7L2 protein by RNA immunoprecipitation using anti-TCF7L2 in COLO320 cells, which have endogenous high
CCAT2 expression. A quantitative analysis using qRT-PCR is shown along with the PCR gel images. (H) Immunostaining of HCT116 clones with vimentin
antibody or DAPI. Stronger vimentin signal as seen in epithelial–mesenchymal transition was observed in CCAT2-overexpressing clones than in cells with
basal CCAT2 expression. (I ) CCAT2 increases the mRNA expression levels of CD44 and VIM in HCT116 clones. The data are presented as mean6 SEM from
at least three independent experiments. (*) P < 0.05.
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in CCAT2 expression after LiCl treatment (Fig. 6A). TCF7L2
knockdown using two different siRNAs impaired the LiCl-induced
CCAT2 expression increase in HCT116 cells (Fig. 6B; Supplemental
Fig. S15), suggesting that the effect onWNT signaling was TCF7L2
dependent. In the CCAT2-overexpressing clones, TCF7L2 siRNA
consistently reducedCCAT2 expression, either with or without LiCl
stimulation, indicating that TCF7L2 is necessary for the mainte-
nance of high CCAT2 expression levels (Fig. 6C). The endogenous
expression of CCAT2 was also significantly down-regulated by
TCF7L2 siRNA in KM12SM and COLO320 cells (Fig. 6D,E). These
findings suggest the existence of a complex feedback loop of
CCAT2 and WNT signaling.
Figure 6. Regulation of CCAT2 expression by WNT signaling and SNP variance on CCAT2 expression. (A) CCAT2 expression is induced by lithium
chloride (LiCl) in three colon cancer cell lines. AXIN2 or TOP-Flash luciferase activity served as a positive control for the activation of WNT signaling. The
data are presented as mean 6 SD (n = 3). (B) TCF7L2 is indispensable for LiCl-induced CCAT2 expression. HCT116 cells were treated with TCF7L2 siRNA
(siGENOME SMARTpool TCF7L2; Dharmacon) for 24 h and then stimulated with LiCl for another 24 h. CCAT2 expression levels were measured by qRT-
PCR. (C ) TCF7L2 siRNA down-regulates CCAT2 expression in overexpressing OC2 clone, either with or without LiCl stimulation. (D,E ) TCF7L2 siRNA
(sc43525, Santa Cruz) down-regulates CCAT2 expression in KM12SM cells and COLO320 cells. The data are presented asmean6 SEM (n = 3); (*) P < 0.05
when compared with the respective control. (F ) Comparison of CCAT2 expression in cohort of CRC samples from Italy with GG and TT genotype showed
higher CCAT2 expression associated with the G allele. The P-value was calculated using the Mann-Whitney test. The data are presented as box-whisker
plots. (G,H ) The Pyrosequencing data showed a higher percentage of the G allele in the CCAT2 transcripts than its genomic DNA counterpart in het-
erogeneous rs6983267 cell lines (DLD1 and KM12SM) and CRC patient samples with GT genotype. COLO320, which is TT genotype, served here as
a negative control.
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rs6983267 alleles affect CCAT2 expression and function
The discovery of CCAT2 and its role in CRC suggests that it may
underlie the mechanism of the rs6983267 SNP-conferred cancer
risk. We first test if rs6983267 status affects CCAT2 expression in
patient samples. We genotyped the rs6983267 SNP in previously
profiled MSS samples (Italian, Japan, and Australian cohorts) (Fig.
1B) and separated them into GG, GT, and TT groups. We did not
observe a significant difference (P = 0.450) in CCAT2 expression
levels between the GG (n = 52) and TT (n = 45) groups (Supple-
mental Fig. S16). However, further separation of the groups ac-
cording to the individual cohort revealed that the difference (P =
0.009) is significant in the Italian cohort, which has the largest
sample size (Fig. 6F). Inconsistently, there was no significant dif-
ference in CCAT2 expression between the GG and TT alleles in 93
CRC patients from the United Kingdom (data not shown). These
data suggest that the effect of the rs6983267 allele on CCAT2
expression levels may be very subtle, and for detection better-
controlled experimental designs are needed.
To address this question, we took advantage of CRC cell lines
(DLD1 and KM12SM cells) with a heterogeneous rs6983267 ge-
notype, to measure the amount of CCAT2 transcript produced
from different alleles. We amplified the region spanning the SNP
using genomic DNA or RNA as template and sequenced the PCR
products by Pyrosequencing, a method that allows for accurate
and quantitative analysis of DNA sequence (Fakhrai-Rad et al.
2002). In both DLD1 and KM12SM cells, the percentage of G allele
is slightly (;6%), but significantly, higher in RNA samples than
the corresponding genomic DNA samples (Fig. 6G). These data
prompted us to determine the allele ratio in genomic DNA and
RNA of CRC samples with GT genotype. As shown in Figure 6H,
three out of four samples showed consistent findings—that is,
significantly higher percentage (7%–15%) of G allele in RNA than
in DNA samples. These data suggest that the G allele of rs6983267
produces more CCAT2 transcripts than the T allele.
We next determined whether CCAT2 transcripts containing
G or T have different biological functions.Wemutated the SNP site
of the retrovirus CCAT2 construct from G to T and transfected
HCT116 cells with CCAT2-G or CCAT2-T retroviruses. Although
we observed higher MYC expression (both RNA and protein) in
CCAT2-G- than CCAT2-T-transfected cells (Supplemental Fig.
S17A,B), the difference becomes insignificant after normalizing to
CCAT2 expression levels (Supplemental Fig. S17C). To test whether
the rs6983267 allele affects CCAT2’s regulation of MYC in CRC
patients, we analyzed CCAT2 and MYC expression correlation in
previously genotyped MSS CRC samples. A significant positive
correlation between CCAT2 and MYC expression was observed in
GG samples (n = 52, coefficient = 0.43; P = 0.001), but not in TT
samples (n = 45, coefficient = 0.26; P = 0.078) of CRCs (Supple-
mental Fig. S18). Furthermore, by using the Vienna RNA Secondary
Structure Package (http://www.tbi.univie.ac.at/;ivo/RNA/), we
identified that the CCAT2 G and T alleles have distinct con-
formations (Supplemental Fig. S19). Although further studies are
needed to verify the different biological functions of the rs6983267
G and T alleles, our data indicate that the specific alleles may also
differentially affect MYC expression.
Discussion
We report the identification of CCAT2, a novel lncRNA encom-
passing the cancer-related rs6983267 SNP and located in a highly
conserved genomic region enriched for markers of regulatory
elements, such as H3K4me1, p300, and H3K27ac (Pomerantz et al.
2009). This lncRNA is expressed at high levels in MSS CRC tumor
tissues and influences MYC levels, but has very low-level expres-
sion in normal colon tissues. This could explain how this new gene
has escaped identification, until now, after genome-wide associa-
tion studies identified the association between the SNP rs6983267
and cancer risk, as well as why tiling arrays did not identify it. A
recent study showed that removal of the region encompassing the
rs6983267 SNP confers resistance to intestinal tumors induced by
the APCmin mutation in mice (Sur et al. 2012). Because we also
cloned a novel transcript encompassing this SNP region from
mouse tissue, it can be envisioned that deletion of the region also
leads to removal of the CCAT2 transcript. Thus, this study lends
further support to the oncogenic function of CCAT2 in CRC
pathogenesis. In addition, the findings of decreased MYC expres-
sion and reduced TCF7L2 binding upstream of MYC in knockout
mice from the same study are also consistentwith our findings that
CCAT2 regulates MYC transcriptional activity.
CCAT2-enhanced invasion and metastasis appear to occur
through the MYC-regulated miRNAs miR-17-5p and miR-20a. The
role of MYC inmetastasis has been controversial, and a recent pub-
lication shows that, in breast cancer, MYC suppresses metastasis
by direct transcriptional silencing of integrins (Liu et al. 2012). Of
interest, miR-20a was identified as being overexpressed in the
transition from colonmucosa to early adenoma, andwas predicted
to target multiple WNT pathway genes (Bartley et al. 2011). The
observation according to which CCAT2-enhanced invasion is
mediated by MYC-regulated miRNAs and also possibly by other
pro-metastatic targets such as CDC25A (Feng et al. 2011), rather
than by MYC itself, suggests a complex regulatory network that
needs to be further explored in the future. This is also in agreement
with the recent observation by The Cancer Genome Atlas (TCGA)
Consortium that MYC-driven transcriptional activation and re-
pression play important roles in colon cancer (TheCancerGenome
Atlas Network 2012). It is also possible that the effect of CCAT2
on metastasis is mediated through its general activation of WNT
signaling (Nguyen et al. 2009; Yu et al. 2012) or another unknown
mechanism.
The TOP-Flash luciferase assay suggests increased WNT ac-
tivity inCCAT2-overexpressing cells. Therefore, we postulated that
the increasedMYC transcription could result from increased WNT
activity, because MYC itself represents a well-established WNT
target (He et al. 1998). Recent studies have identified RNA–protein
interaction as one of the main regulatory mechanisms of lncRNAs
(Rinn and Chang 2012). Coimmunoprecipitation of CCAT2 (RNA)
and TCF7L2 (protein) suggests that CCAT2 may broadly regulate
WNT target genes by binding to TCF7L2 and modulating its
transcriptional activity. Various mechanisms can be envisaged to
explain how the CCAT2/TCF7L2 association can enhance WNT
activity. We speculate that CCAT2may affect TCF7L2-driven gene
transcription through modulating association of TCF7L2 with its
partners, which include the negative regulators Groucho/TLE and
CTBP1 and the activator CTNNB1 (Clevers 2006), or changing
TCF7L2 protein function by bridging TCF7L2 with other proteins
in the transcription complexes. Alternatively, the association of
CCAT2 with TCF7L2 may modify the protein structure and en-
hance its function. Regarding the mechanism of MYC regulation,
it is also possible that CCAT2 participates in the loop formation
between the genomic loci of rs6983267 with MYC promoter
(Pomerantz et al. 2009) and works together with the enhancer el-
ement to activate MYC transcription. Notably, we also show that
WNT signaling regulates CCAT2 expression, suggesting a feedback
CCAT2 in colorectal cancer pathogenesis
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loop between CCAT2 and WNT signaling as previously shown for
other targets such as CDH1 (Heuberger and Birchmeier 2010) and
AXIN2 (Lustig et al. 2002).
We demonstrated CCAT2’s ability to underlie chromosomal
instability,manifested by the loss or gain of large portions or whole
chromosomes, eventually resulting in aneuploidy, a characteristic
trait ofMSSCRCs. These data support a scenario inwhich, together
with mutations in coding genes such as APC (Fodde et al. 2001;
Kaplan et al. 2001) and BUB1 (Cahill et al. 1998), CCAT2 contrib-
utes to CIN in colon cancer. This is likely to occur throughCCAT2’s
effects on downstream mediators such asMYC and/or other WNT
target genes. The direct involvement of MYC in CIN has been
previously demonstrated by showing that
transient excess of MYC activity could
elicit genomic instability and carcino-
genesis (Felsher and Bishop 1999). In-
versely, Myc deletion rescues APC defi-
ciency in the mouse intestine (Sansom
et al. 2007). Thus, it is plausible thatMYC
acts as a mediator of CCAT2-induced CIN
phenotype. Furthermore, the MIR17HG
miRNAs, known to be MYC regulated,
can also affect CIN as evidenced by dif-
fuse large B-cell lymphoma that has high
levels of these miRNAs and nonrandom
chromosomal abnormalities (Li et al.
2009). Alternatively, the CIN-inducing ef-
fect can result from the general activation
of WNT signaling by CCAT2. This hy-
pothesis is supported by previous findings
that CTNNB1/TCF7L2-mediated transcrip-
tion (Aoki et al. 2007) or ectopic expres-
sion of the WNT target gene conductin
(AXIN2) (Hadjihannas et al. 2006) directly
induces CIN. However, it should be noted
that although CIN can be the underlying
mechanism for CCAT2-promoted tumor
growth and metastasis, mechanistic con-
nections of these phenotypes are not
established in this study.
Finally, our Pyrosequencing data on
heterogeneous cell line models and CRC
samples suggest that rs6983267 status af-
fects the CCAT2 expression, providing an
additional mechanism linking the risk al-
lele of rs6983267 with higher CRC risk.
Although we demonstrated that WNT
signaling regulates CCAT2 expression, it
remains to be determined if this accounts
for the SNP-caused differential expression
of CCAT2. In addition, in CRC patients
with GG (but not TT) genotype, CCAT2
shows significant association with MYC
expression levels, suggesting that the SNP
status may also affect CCAT2 function as
an RNA transcript. Although most of the
previous studies failed to identify a corre-
lation between this SNP and MYC expres-
sion, recent research found higher MYC
expression in CRC samples containing GG
alleles, probably due to the improved pu-
rity of the cancer tissues owing to the use
of laser microdissection (Takatsuno et al. 2012). Our findings on
SNP-induced differentialCCAT2 expression and function, together
with theDNA enhancer element (Pomerantz et al. 2009; Tuupanen
et al. 2009), provide an explanation on the cancer risk conferred by
the rs6983267 risk allele (Fig. 7).
The discovery of CCAT2 introduces a novel mechanism for
the involvement of ncRNAs inWNT signaling and colon cancer
pathogenesis. The recent findings showing that the CIN phe-
notype is a predictive marker for survival and may be used to
select high-risk patients with stages II and III CRC (Watanabe
et al. 2012), combined with the specific involvement of CCAT2
in MSS CRCs indicate that CCAT2 has the potential to become
Figure 7. A model of CCAT2 locus involvement in CRC. (Upper panel) An ;335-kb DNA loop brings
the rs6983267 genomic region close to the MYC locus, and this physical association may contribute to
the enhancer function of the SNP-containing region on MYC transcription (Pomerantz et al. 2009).
(Lower panel) The enhancer region is transcribed into a long noncoding RNA (CCAT2), and the SNP
status affects CCAT2 expression by an as-yet-unknown mechanism. The CCAT2 transcript up-regulates
WNT activity and increases expression levels of WNT target genes (including MYC ). This regulation by
CCAT2, possibly through its physical interaction with TCF7L2, may lead to genomic instability and
promote cell growth. We demonstrated that MYC-regulated miR-17-5p and miR-20a participate in the
CCAT2-enhanced cell invasion and speculate that other mechanisms, such as MYC-related mechanisms
(CDC25A) or enhanced WNT signaling (VIM and CD44), may exist to coordinate the metastatic phe-
notype elicited by CCAT2. Finally, we demonstrated that CCAT2 expression is regulated by transcrip-
tional factors TCF7L2, indicating a positive feedback loop between CCAT2 and WNT signaling. Our
findings provide an additional explanation on the SNP-conferred CRC risk. (Black) Demonstrated; (gray)
hypothesized interactions.
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a useful diagnostic and/or prognostic marker, although further
validation in larger cohorts and by multiple independent studies
is necessary.
Methods
Patient samples
One hundred and ninety-one colorectal cancer samples and 70
non-neoplasticmucosa samples were used in this study. The tumor
and control samples were obtained from three different sources: an
Italian cohort from the University of Ferrara (CRC = 81 and normal
colon mucosa = 25), a Japanese cohort from the University of
Kyushu (CRC = 45 and paired normal colon mucosa = 45), an
Australian cohort from Princess Alexandra Hospital (CRC = 65),
and aC-CFR cohort fromNorthernAmerican colon cancer patients
with MSS, CIMP-negative colon cancer at three participating
centers of the Colorectal Cancer Family Registry (Mayo Clinic,
Rochester, Minnesota, USA; Mount Sinai Hospital, Ontario, Can-
ada; and Cleveland Clinic, Cleveland, Ohio, USA) (CRC = 24 and
paired normal colon mucosa = 24). Tissue samples were obtained
from fresh surgical specimens frozen in liquid nitrogen and stored
at 80°C. All the samples were obtained with the patients’ in-
formed consent and were histologically confirmed.
Breast tumors were selected from the tumor bank at the
ErasmusMedical Center (Rotterdam, TheNetherlands). The frozen
tumor samples were collected from female patients with breast
cancer who entered the clinic from 1979 to 1998 and for whom
detailed clinical follow-up data and tumor RNA forCCAT2 analysis
were available (Sieuwerts et al. 2007; Smid et al. 2011). The protocol
for studying biologicalmarkers associatedwith disease outcomewas
approved by the medical ethics committee of the Erasmus Medical
Center (MEC 02.953).
The British CRC samples were derived from a set of CRC pa-
tients recruited as part of the CORGI study who had known geno-
types at the 8q24 tagSNP (Tomlinson et al. 2007).
RNA isolation, cDNA synthesis, and quantification of specific
RNA species
RNA was extracted using the TRIzol protocol (Invitrogen) and
DNase-digested (Ambion); the quality of the RNA was assessed
using agarose gel electrophoresis. cDNAwas synthesized using the
SuperScript III cDNA kit (Invitrogen), and diluted cDNA was used
for RT-PCR analysis using iQ SYBR Green Supermix (Bio-Rad)
with the appropriate primers (Supplemental Table S2). The 2DCt
method was used to calculate the relative abundance of RNA
genes compared with GAPDH expression. qRT-PCR analysis for
miRNAs was performed with the TaqMan MicroRNA Assay Kit
(Applied Biosystems). Primers and probes for miR-17, miR-20a,
miR-146a, let-7a, and RNU6-6P snRNA were purchased from Ap-
plied Biosystems. The 2DCt method was used to calculate the
relative abundance of miRNA genes compared with RNU6-6P
expression.
Cell lines
COLO320DM, HCT116, RKO, and HEK293 cells were obtained
from the American Type Culture Collection and validated by the
Characterized Cell Line Core at The University of Texas MD
Anderson Cancer Center using STR DNA fingerprinting.
Stable cell line generation
Stable HCT116 cells for CCAT2 overexpression experiments were
produced by pMX retrovirus or pcDNA3.1 expression vector
transfection. For the pcDNA3.1 single clones, we screened CCAT2
expression in the HCT116 cells transfected with CCAT2 construct
and randomly chose two cloneswith highCCAT2 expression (OC1
and OC2), and one clone with basal level of CCAT2 expression
(E2). E1 was originated from the HCT116 cells transfected with the
empty pcDNA3.1 vector.
COLO320 stable cells forCCAT2 knockdown experiments were
generated using pRS-Retro-GFP/neo vector retrovirus (OligoEngine)
or the Knockout Single Vector Inducible RNAi System (Clontech).
Virus production
The CCAT2-containing genomic region was amplified with a
primer combination (CCAT2 F2 and R2) from HCT116 genomic
DNA with Pfu polymerase (Invitrogen). After sequencing of the
PCR product, we cloned it into the pMX plasmid. Then we pro-
duced CCAT2-containing retrovirus in 293 GP2 cell lines and used
virus-containing supernatant to infect HCT116 cells. After in-
fection, HCT116 cells were grown in complete media containing
puromycin (1 mg/mL). The shRNAs against CCAT2 (Supplemental
Table S2) were inserted into the pRS-Retro-GFP/neo vector ac-
cording to the manufacturer’s protocol (OligoEngine).
Plasmid production
The sequence used for retrovirus production was also cloned into
a pcDNA3.1+ vector. The pcDNA CCAT2 plasmid was linearized
with BglII and transfected into HCT116 cells using Lipofectamine.
Selection with G418 (0.5 mg/mL) was carried out until single col-
onies were generated. The tet-on inducible shCCAT2 clones (Sup-
plemental Table S2) were generated using the Knockout Single
Vector Inducible RNAi System according to the manufacturer’s
instructions.
CCAT2 in situ hybridization
The frozen tissue slides of two MSS CRCs, two MSI-H CRCs, and
two normal mucosae were incubated with a double-DIG-labeled
CCAT2 probe or control RNU6-6P snRNA probe (Exiqon) and
detected with a polyclonal anti-DIG antibody and alkaline
phosphatase–conjugated secondary antibody (Ventana) using
NBT-BCIP as the substrate. The signal intensities of CCAT2 and
RNU6-6P expression were quantified by using the intensity mea-
surement tools of the Image-Pro Plus software package (Media
Cybernetics).
In vivo tumorigenic assay
Swiss nu-nu/Ncr nude mice (spontaneous mutant T-cell-deficient
mice) were obtained from the Animal Production Area of the De-
partment of Experimental Radiation Oncology at MD Anderson
Cancer Center. The mice were maintained under specific pathogen-
free conditions and used in accordance with institutional guide-
lines. HCT116 cells (1 3 106) were injected subcutaneously into
the right flanks of the mice, and tumor size was measured weekly
for 4 wk.
In vivo metastasis assay
A midline incision was made on the left side of the flank, and the
spleen was exteriorized. HCT116 cells (13 106 cells) were injected
into the spleen, after which the wound was closed with surgical
metal clips. The mice were sacrificed after 8 wk, and their spleens
and livers were removed and examined for tumor metastases on
the surface of the liver. The liver specimens were formalin fixed
and paraffin embedded for histological analysis.
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In vitro migration assays
We used two assays: In the first, HCT116 cells (200,000 cells in
200 mL of serum-freemedia) were seeded into a Transwell insert in
a 24-well format (8 mm; BD Biosciences). To the bottom part of
the well, 800 mL of medium with serum was added. Twenty-four
hours after seeding, cells were fixed with paraformaldehyde and
stained with crystal violet/methanol solution. Cells at the top of
the Transwell were removed using a cotton swab, and photos of
the Transwells were taken using Geldoc (Bio-Rad). The intensity
of the crystal violet staining in each Transwell was evaluated us-
ing Photoshop software (Adobe Systems) and compared among
the different treatments.
The second type of assay, a cell migration assay, was per-
formed according to the protocol previously described (Spannuth
et al. 2009). Cells were suspended in serum-free media (65,000
cells/insert) and seeded onto the gelatin-coated inserts. The cells
that migrated to the bottom of the wells were fixed, stained, and
counted using a microscope. For each well, 10 different fields were
counted, and the average number of cells was determined. Both
types of assays were performed in triplicate experiments.
SiRNA treatment
Cells were seeded onto 24-well or six-well plates. After reaching
50% confluence, cells were transfected with 50 nM siRNA by
Lipofectamine 2000 (Life Technologies) for 48 h before collecting
RNA or protein for analysis.
Genomic instability analysis
Cells were exposed to Colcemid (0.04 mg/mL) for 25 min at 37°C
and to hypotonic treatment (0.075 M KCl) for 20 min at room
temperature, and then were fixed in a methanol and acetic acid
mixture (3:1 by volume) for 15 min and washed three times in the
fixative. The slideswere air-dried, stained in 4%Giemsa, and coded
for the blind analysis. Later, the slides were decoded for the eval-
uation of results. Slides were analyzed for several parameters, in-
cluding chromosome aberrations (as evidenced by both chromo-
some- and chromatid-type breaks), fragments, tetraploidy, fusions,
and formation of tri-radials.
Spectral karyotyping
Spectral karyotyping was performed according to the manufac-
turer’s protocol using Human Paint probes (Applied Spectral Im-
aging, ASI). Images were captured using a Nikon 80i microscope
equipped with Spectral karyotyping software from ASI.
CREST staining
After fixation, cells were incubated for 1 h at room tempera-
ture with human serum from scleroderma patients (kindly pro-
vided by Maureen Mayes from the University of Texas–Houston
Medical School) that produced, during the course of their dis-
ease, anti-centromere antibodies used for staining. Staining was
visualized using FITC-conjugated donkey anti-human antibody.
Beta-tubulin was detected using Cy3-conjugated antibody (Sigma-
Aldrich).
Subcellular fractionation
The separation of nuclear and cytosolic fractions was performed
using the PARIS Kit (Life Technologies) according to the manu-
facturer’s instructions.
RNA immunoprecipitation
We used the Magna RIP Kit (Millipore) according to the manu-
facturer’s instructions. Cells were prepared in RIP lysis buffer, and
the RNA–protein complexes were immunoprecipitated using
anti-TCF7L2 or normal goat IgG (control). RNA was purified
using phenol:chloroform:isoamyl alcohol and subjected to re-
verse transcription-PCR or real-time PCR analysis (Supplemental
Table S2). Control amplification was carried out on input RNA
before immunoprecipitation.
TOP-Flash WNT reporter
Cells were transfected with 250 ng of the TOP-FLASH or FOP-
FLASH reporter constructs together with 25 ng of the Renilla
luciferase vector. Luciferase activity was measured by the Dual–
Luciferase Reporter Assay System (Promega) 48h after transfection,
and TOPor FOP valueswere normalized to Renilla values. The TOP/
FOP ratios were calculated and used as indicators of the endoge-
nous level of WNT signaling.
Immunofluorescent assay
Cells were seeded on a 96-well plate. After 48 h, the cells were
permeabilized and fixed in 4% paraformaldehyde in PBS buffer at
room temperature for 15 min. The cells were then incubated with
anti-vimentin (V9, Novus) overnight and finally incubated with
secondary antibody and DAPI for 1 h. All matched samples were
photographed using an immunofluorescence microscope and
identical exposure times. Each experiment was performed in trip-
licate and repeated three times.
Allele quantification by Pyrosequencing
Weused the Pyrosequencing technology (QIAGEN) tomeasure the
frequency of the G and T alleles of the CCAT2 transcript. The
principles of the method and analysis have been previously
reported (Wang and Elbein 2007). In our study, nested PCR re-
actions were done for each sample. The first PCR was performed
using the primers 1-F (TTTAGCAGCTGCATCGCTCCATAG) and
2-R (CTCCCTCCCCCACATAAAAT). The second PCR combined
a universal biotinylated primer for subsequent single-strand
DNA capture for the Pyrosequencing reaction. One microliter
of the first PCR was used for the nested amplification, and a
reaction was performed to capture the forward strand using
the primers SNP/F1 (GGGACGAATAAACTCTCCTCCTAC), SNP/
RU1 (GGGACACCGCTGATCGTTTACTCCCTCCCCCACATAAAAT),
and the universal biotinylated primers UBP (Bio-GGGACACCG
CTGATCGTTTA). An independent PCR reaction was performed to
capture the reverse strand using the primers SNP/FU2 (GGGA
CACCGCTGATCGTTTAGAGGTGTAGCCAGAGTTAATACCC), SNP/
R2 (CTCCCTCCCCCACATAAAAT), and UBP (Bio-GGGACACC
GCTGATCGTTTA). After cleanup in a vacuum prep station, the
single-strand DNAwas combined with sequencing primers to read
the forward (SNP/S1, AGCTCAGCAGATGAAA, and the sequence
to analyze GG/TCACTG) and reverse (SNP/S2, TCTTTGTACTT
TTCTCAGTG, and the sequence to analyze A/CCTTTCATC) strands
of the target SNP. Each measurement was performed in duplicate,
and the values from the forward and reverse strands was combined
to give the frequency of the G and T alleles.
Statistical analysis
For the colorectal cancer samples, the statistical analyses were
performed in R (version 2.14.2). The Shapiro-Wilk test was ap-
plied to determine whether data followed a normal distribution.
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Accordingly, the t-test or the nonparametric Mann-Whitney-
Wilcoxon test was applied to assess the relationship between
CCAT2 expression levels and clinical parameters. Fisher’s exact test
was used to assess the association betweenCCAT2 and the number
of metastases in mice. For the breast cancer cohorts, data were
analyzed using the STATA statistical package, release 9 (STATA
Corp.) and SPSS 15.0 (IBM Corporation). We investigated the
prognostic value of the clinical and biological variables with me-
tastasis-free survival (MFS) as the end point using Cox univariate
and multivariate regression analyses. CCAT2 RNA levels were an-
alyzed as a log-transformed continuous variable and also, for vi-
sualization in Kaplan-Meier survival analysis, as a dichotomized
variable based on the median level of CCAT2 RNA, with the log-
rank test used to evaluate differences. A Spearman’s rank-order
correlation test was applied to measure the strength of association
between the expressions of CCAT2 and MYC in colorectal cancer
samples and between CCAT2 RNA and CIN score in breast cancer
samples. All tests were two sided, and P < 0.05 was considered
statistically significant.
Data access
The CCAT2 RNA sequence reported in this paper has been de-
posited in GenBank (http://www.ncbi.nlm.nih.gov/nuccore)
under accession number GQ911591.
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